Access-and-benefit-sharing, explained (for kanna readers)

Most kanna product pages talk about calm focus. Fewer talk about who owns the right to commercialize an indigenous South African plant and the traditional knowledge around it. Access-and-benefit-sharing (ABS) is the policy vocabulary for that problem. This post explains the idea without turning kanna.clinic into a law firm or a supplier directory.

We sell nothing and are not affiliated with any brand.

The basic ABS story

Countries that hold biodiversity and communities that hold traditional knowledge have spent decades pushing back against “helicopter bioprospecting” — research or product development that extracts value abroad while leaving little behind. The Convention on Biological Diversity and the Nagoya Protocol give international shape to prior access rules and fair benefit-sharing when genetic resources (and often associated traditional knowledge) are utilized (CBD ABS / Nagoya Protocol, reviewed 2026-07-21).

In one sentence: access is not automatically free just because a plant grows in soil.

Why kanna is a textbook ABS species

Sceletium tortuosum is indigenous to South Africa, with documented traditional use among San and Khoi communities and a modern commercial extract market abroad. That combination — traditional knowledge + exportable extract + wellness demand — is exactly where ABS friction appears.

South Africa implements biodiversity and bioprospecting rules under national legislation (including the NEMBA framework and related ABS measures). Commercial players may need permits and benefit-sharing arrangements depending on activity. Details and caveats: regulatory status and ethical sourcing.

The Zembrin / San Council example (history, not an ad)

Public accounts describe formal benefit-sharing connected to the development pathway of the standardized extract known as Zembrin® (HG&H Pharmaceuticals) and San representative structures. It is often cited as an early worked example of ABS in this species. On this site it functions as governance literacy, not a product endorsement (standardization page).

Later brands that print “ethically sourced” without documents are not automatically in the same category.

Red flags for readers

Wild-harvest romance with no permit story
Refusal to name cultivation country or farm system
“Traditional” used only to dress disease claims (also a U.S. dietary-supplement problem as of 2026-07-21)
Benefit-sharing claims with no counterparty named

What ABS is not

ABS compliance does not mean a product is medically effective, appropriate with your SSRI, or legal to market with drug claims. Those are separate axes (safety; FDA dietary supplements).

U.S. CSA snapshot as of 2026-07-21: not DEA-scheduled on public scheduling education pages (DEA scheduling) — again, orthogonal to South African ABS duties for commercial actors.

Closing

If you care about kanna beyond a mood slogan, ask where the plant came from and whether anyone at origin shares in the value. That question belongs next to assay literacy — not after it.

Crisis resources if this research sits beside mental-health distress: 988, text HOME to 741741, 911.

ABS vs “fair trade” stickers

ABS is not the same as a voluntary fair-trade certification logo. Fair-trade systems are usually private standards. ABS under the Nagoya Protocol and South African law is about sovereign rights over genetic resources and mutually agreed terms with providers and knowledge holders. A brand can carry a lifestyle “ethical” badge and still lack permits or benefit-sharing for indigenous biological resources.

For buyers, that means you may need to ask two parallel questions:

Labor and farm practice — wages, pesticides, worker safety (ordinary supply-chain ethics).
ABS and traditional knowledge — who authorized commercial utilization, and who shares benefits.

Only the second is what this post is about. Both can fail independently.

Monetary and non-monetary benefits

Benefit-sharing is not only a royalty check. Public ABS materials and real agreements often mix:

Monetary — milestones, royalties, scholarship funds, community trusts
Non-monetary — training, joint publications, technology transfer, local employment, conservation support

A company that says “we donated once to a charity” has not automatically satisfied ABS. Conversely, a well-structured non-monetary package can be meaningful if the rights-holders agreed to it. The test is agreement and documentation, not the marketing adjective “generous.”

Research use vs product sale

Academic fieldwork, commercial extract scale-up, and finished dietary-supplement retail can trigger different obligations depending on national law and the activity’s purpose. Readers sometimes assume “I only sell capsules in the U.S., so South African rules do not apply to my supplier.” In practice, your supplier’s compliance still determines whether the upstream harvest or cultivation was lawful and whether traditional knowledge was respected. Downstream brands that never ask are choosing ignorance, not neutrality.

How this ties to quality on the bottle

Undocumented wild harvest is not only an ethics problem. It correlates with:

Unstable alkaloid profiles (see fermented vs raw)
Species confusion risks
Incentives to mislabel biomass when demand spikes

Ethical provenance and analytical transparency reinforce each other. Start with how to read a kanna extract label and the ethical sourcing pillar.

This content is for educational purposes only and does not constitute medical or legal advice. kanna.clinic does not sell substances and is not a clinic.

This post was drafted by AI and reviewed by our editorial team. Last updated 2026-07-21.